Literature DB >> 24240576

Biased agonism: a novel paradigm in G protein-coupled receptor signaling observed in acquired hypocalciuric hypercalcemia.

Noriko Makita1, Taroh Iiri.   

Abstract

The classical model of G protein-coupled receptor (GPCR) activation is the two-state model, in which the GPCR exists in equilibrium between an active and inactive state. Based on this model, GPCR ligands have been classified as agonists, inverse agonists, or antagonists depending on their actions in shifting this equilibrium. Recently, however, accumulating evidence has indicated that GPCRs may exist in multiple active and inactive conformational states. In this situation, each ligand recognizes and stabilizes a specific conformation of the GPCR, leading to a set of specific biological effects. Based on this new model, a unique agonist or a combination of the usual agonist and an allosteric modulator may enable activation of a specific signaling pathway via a GPCR that activates multiple signals (biased agonism, functional selectivity). The calcium-sensing receptor autoantibody that we have identified in the serum of a patient with acquired hypocalciuric hypercalcemia (AHH) is the first example of a biased allosteric modulator of a GPCR working in a pathophysiological context. Our findings may indicate the presence of physiological allosteric modulators and provide new directions for the future drug development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24240576     DOI: 10.1507/endocrj.ej13-0453

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  4 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.

Authors:  Katie Leach; Fadil M Hannan; Tracy M Josephs; Andrew N Keller; Thor C Møller; Donald T Ward; Enikö Kallay; Rebecca S Mason; Rajesh V Thakker; Daniela Riccardi; Arthur D Conigrave; Hans Bräuner-Osborne
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

2.  Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody.

Authors:  Noriko Makita; Takao Ando; Junichiro Sato; Katsunori Manaka; Koji Mitani; Yasuko Kikuchi; Takayoshi Niwa; Masanori Ootaki; Yuko Takeba; Naoki Matsumoto; Atsushi Kawakami; Toshihisa Ogawa; Masaomi Nangaku; Taroh Iiri
Journal:  JCI Insight       Date:  2019-04-18

3.  Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.

Authors:  Noriko Makita; Tomohiko Sato; Yuki Yajima-Shoji; Junichiro Sato; Katsunori Manaka; Makiko Eda-Hashimoto; Masanori Ootaki; Naoki Matsumoto; Masaomi Nangaku; Taroh Iiri
Journal:  J Biol Chem       Date:  2016-09-06       Impact factor: 5.157

Review 4.  Recent advances in understanding the extracellular calcium-sensing receptor.

Authors:  Matilde Colella; Andrea Gerbino; Aldebaran M Hofer; Silvana Curci
Journal:  F1000Res       Date:  2016-10-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.